Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective “Real-World Study”

Published:February 14, 2022DOI:



      Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies. However, it remains unclear which drug should be administered first.

      Patients and Methods

      This French observational study was prospectively conducted in 11 centers between June 2017 and September 2019. All consecutive patients with chemorefractory mCRC and receiving FTD/TPI and/or R were eligible. The aim was to evaluate the efficacy and tolerability of FTD/TPI and/or R in real-world setting with adjusted analysis.


      A total of 237 mCRC patients (25% R and 75% FTD/TPI) were enrolled. As compared to R, FTD/TPI patients were significantly older and with more metastatic sites. Median OS and PFS were respectively 6.2 and 2.4 months in the FTD/TPI and 6.6 and 2.1 months in the R group. After matching 46 paired patients according to a propensity score, a trend to a longer OS (P = .58), and a significantly longer PFS (P = .048) were observed in the FTD/TPI group. In the 24% of patients receiving the R/T or T/R sequence, median OS from first treatment was similar. Tolerability profiles were similar to published data and dose reductions were more frequent in the R group.


      Efficacy and safety results in this real-world prospective study are in line with phase III trials. In a matched population, PFS was significantly longer in the FTD/TPI group. Despite a limited number of patients, clinical outcomes seemed similar in patients treated with the T/R or R/T sequence.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yamazaki K
        • Nagase M
        • Tamagawa H
        • et al.
        Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
        Ann Oncol. 2016; 27: 1539-1546
        • Loupakis F
        • Cremolini C
        • Masi G
        • et al.
        Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
        N Engl J Med. 2014; 371: 1609-1618
        • Heinemann V
        • von Weikersthal LF
        • Decker T
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1065-1075
        • Mayer RJ
        • Van Cutsem E
        • Falcone A
        • et al.
        Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
        N Engl J Med. 2015; 372: 1909-1919
        • Grothey A
        • Van Cutsem E
        • Sobrero A
        • et al.
        Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 303-312
        • Unseld M
        • Drimmel M
        • Siebenhüner A
        • et al.
        Optimizing treatment sequence for late-line metastatic colorectal cancer patients using trifluridine/tipiracil and regorafenib.
        Clin Colorectal Cancer. 2018; 17: 274-279
        • Sonbol MB
        • Benkhadra R
        • Wang Z
        • et al.
        A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
        Oncologist. 2019; 24: 1174-1179
        • Cremolini C
        • Rossini D
        • Martinelli E
        • et al.
        Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program.
        Oncologist. 2018; 23: 1178-1187
        • Patel AK
        • Duh MS
        • Barghout V
        • et al.
        Real-world treatment patterns among patients with colorectal cancer treated with trifluridine/tipiracil and regorafenib.
        Clin Colorectal Cancer. 2018; 17: e531-e539
        • Bekaii-Saab TS
        • Ou F-S
        • Ahn DH
        • et al.
        Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
        Lancet Oncol. 2019; 20: 1070-1082
        • Adenis A
        • de la Fouchardiere C
        • Paule B
        • et al.
        Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
        BMC Cancer. 2016; 16: 412
        • Ducreux M
        • Petersen LN
        • Öhler L
        • et al.
        Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
        Eur J Cancer. 2019; 123: 146-154
        • Tabernero J
        • Argiles G
        • Sobrero A
        • et al.
        Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.
        ESMO Open. 2020; 5e000752
        • Moriwaki T
        • Fukuoka S
        • Taniguchi H
        • et al.
        Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study.
        Oncologist. 2018; 23: 7-15
        • Moriwaki T
        • Fukuoka S
        • Masuishi T
        • et al.
        Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
        Int J Clin Oncol. 2020; 25: 614-621
        • Masuishi T
        • Taniguchi H
        • Kawakami T
        • et al.
        Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
        ESMO Open. 2019; 4
        • Cremolini C
        • Rossini D
        • Dell'Aquila E
        • et al.
        Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.
        JAMA Oncol. 2019; 5: 343-350
        • Yang Q
        • Huang Y
        • Jiang Z
        • et al.
        Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.
        Onco Targets Ther. 2018; 11: 2467-2473
        • Modest DP
        • Pant S
        • Sartore-Bianchi A.
        Treatment sequencing in metastatic colorectal cancer.
        Eur J Cancer. 2019; 109: 70-83